Cases
Ra Medical Systems, Inc. (NYSE: RMED)
Securities Class Action
Overview
Overview
- Date:
- 5/8/2019
- Company Name:
- Ra Medical Systems, Inc.
- Stock Symbol:
- RMED
- Status:
- Closed/Complete
NEW YORK, May 8, 2019 – Bragar Eagel & Squire, P.C. is investigating potential claims against Ra Medical Systems, Inc. (NYSE: RMED) on behalf of Ra Medical stockholders. Our investigation concerns whether Ra Medical has violated the federal securities laws and/or engaged in other unlawful business practices.
In September 2018, Ra Medical completed its initial public offering (“IPO”), issuing approximately 4.5 million shares of common stock priced at $17.00 per share. On March 14, 2019, the company revealed that its fourth quarter 2018 financial results had been negatively impacted by issues related to the hiring and training of qualified sales personnel and certain production limitations. Since the IPO, Ra Medical stock has declined. As of market close on May 9, 2019, the stock price was $4.07.
If you purchased or otherwise acquired Ra Medical shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
In September 2018, Ra Medical completed its initial public offering (“IPO”), issuing approximately 4.5 million shares of common stock priced at $17.00 per share. On March 14, 2019, the company revealed that its fourth quarter 2018 financial results had been negatively impacted by issues related to the hiring and training of qualified sales personnel and certain production limitations. Since the IPO, Ra Medical stock has declined. As of market close on May 9, 2019, the stock price was $4.07.
If you purchased or otherwise acquired Ra Medical shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.